October 14, 2021 (San Antonio, TX) bioAffinity Technologies today announced that Xavier T. Reveles, MS, CG, has been promoted to Vice President of Operations. Reveles will be responsible for overseeing the commercialization of the Company’s diagnostic products, including CyPath® Lung, a highly accurate, non-invasive test to diagnose early-stage lung cancer.
read moreSeptember 23, 2021 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, announced that the Australian Patent Office issued a Notice of Acceptance for bioAffinity subsidiary OncoSelect’s patent protecting compositions and methods to treat cancer using chemotherapeutic agents conjugated to porphyrins, resulting in targeted delivery of the drugs.
read moreSan Antonio Business Journal (September 16, 2021) More than seven years after its launch, bioAffinity Technologies is on the cusp of commercializing its initial product, the CyPath® Lung cancer diagnostic test. Precision Pathology Services, which has licensed the San Antonio-based company’s technology, has completed its validation of the clinical performance of CyPath® Lung and is now preparing to take the non-invasive test to market.
read moreSeptember 9, 2021 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company advancing innovative cancer diagnostics, announced that Precision Pathology Services, a CAP/CLIA-certified anatomic and clinical pathology laboratory, has fully validated the clinical performance of CyPath® Lung, a non-invasive flow cytometric test for early-stage lung cancer.
read moreAugust 12, 2021 (San Antonio, TX) bioAffinity Technologies, a privately held company focused on early diagnostics and cancer therapeutics, announced publication in the peer-reviewed Journal of Visualized Experiments (JoVE). The paper, entitled Quality-Controlled Sputum Analysis by Flow Cytometry, presents an efficient and effective method to analyze sputum on a flow cytometric platform, allowing for development of high-throughput diagnostic tests for lung cancer and other lung diseases.
read more
bioAffinity Technologies was selected as one of San Antonio’s Top 2020 Innovators. In this video, you will see Maria Zannes, President and Chief Executive Officer, speak about what drives motivation, innovation and success and kick off San Antonio’s premier annual event celebrating the City’s healthcare and bioscience industry.